Form 4: Bristol Myers Squibb Director Acquires DSUs

Bristol Myers Squibb Director Julia A Haller acquired 3,996.367 Deferred Share Units, increasing her beneficial ownership to 37,903.154 units.

Summary

• Julia A Haller, a Director of Bristol Myers Squibb Co (BMY), acquired 3,996.367 Deferred Share Units (DSUs).
• The transaction date for this acquisition was February 1, 2026.
• Each DSU has a conversion or exercise price of $55.05.
• Following this transaction, Julia A Haller beneficially owns a total of 37,903.154 Deferred Share Units.
• Each Deferred Share Unit will convert into one share of common stock upon settlement.
• Settlement occurs when the reporting person ceases to be a director or at a previously specified future date.
• The reported beneficial ownership includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal. While a routine compensation-related acquisition, it increases a director's alignment with shareholder interests, which is generally favorable.

Positives

• A director increasing their beneficial ownership, even through deferred compensation, can signal confidence in the company's future prospects.
• The acquisition of 3,996.367 Deferred Share Units aligns the director's interests more closely with those of shareholders.

Future Outlook

Deferred Share Units will convert into common stock upon settlement, which occurs when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

Industry Context

StockSavvy.ai notes that insider transactions, such as the acquisition of Deferred Share Units by a director, are often monitored by investors as they can provide insights into management's perception of the company's value and future performance. While this specific transaction is part of a compensation plan, it still represents an increase in the director's equity stake in Bristol Myers Squibb, a major pharmaceutical company.

Stakeholder Impact

• Shareholders: Increased alignment of a director's interests with shareholders due to higher beneficial ownership of equity-linked compensation.

Next Steps

• Settlement of Deferred Share Units into common stock upon Julia A Haller ceasing to be a director or at a specified future date.

Key Dates

Recommendation

A single Form 4 filing detailing a director's acquisition of deferred share units, likely as part of a compensation plan, provides a positive signal of insider confidence. However, it is not a standalone event significant enough to warrant a strong buy or sell recommendation. Investors should 'hold' and consider this as a minor positive data point within a broader investment thesis for Bristol Myers Squibb.

Keywords

Bristol Myers Squibb, BMY, Insider Transaction, Form 4, Deferred Share Units, Director Compensation, Equity Acquisition